In the U.S., the average lifetime risk of multiple myeloma is less than 1%. In 2025, the American Cancer Society estimates ...

Regina Toomey Bueno, former oncology admin at Garnet Health, had good insurance, lots of support, and 2 cancer diagnoses. She's one of the lucky ones.

HAVING DISCUSSED IMPORTANT lymphoma and chronic lymphocytic leukemia abstracts from the 66th American Society of Hematology ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: Diagnosis also required -- and still does -- the ...

Despite being the second most common haematologic cancer ... in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of ...

When you have treatment for multiple myeloma, the hope is the medicines will kill your cancer cells and keep your healthy cells. The more the drugs accomplish that, the better you’ll feel.

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible ...

Adherence to ACS nutrition and activity guidelines is associated with a lower risk of death among nonsmoking survivors of obesity-related cancers, researchers found.